Our Story
HeartFlow is a medical technology company revolutionizing precision heart care.
There is no company in the world doing what we do—combining decades of human ingenuity and advanced technology in a completely novel way. We are passionate about transforming the diagnosis and management of coronary artery disease and continue to innovate, pushing into new frontiers and forging incredible partnerships along the way. Learn more about our story below.
The HeartFlow Story
Hear from our founders and customers around the world who are using our innovative technology as they tell the HeartFlow story and describe what makes our company and technology so transformational.
HeartFlow Virtual Tour & Product Overview
Take a virtual tour with leaders from our organization as they explain step-by-step how the HeartFlow technology works, the problem it is solving and how HeartFlow continues to innovate.
The HeartFlow Difference
Physicians and patients agree that the HeartFlow Analysis is a revolutionary technology that is dramatically improving the care for patients with coronary artery disease. Hear their stories below.
Our History
1995
Began development of image-based modeling for coronary blood flow
Charles Taylor PhD: expert in computational fluid dynamics at Stanford University
Christopher Zarins MD: chair of vascular surgery at Stanford University
2010
Founded HeartFlow in Silicon Valley, California
2011
Awarded CE Mark
Commercially available in Europe
2014
Received U.S. FDA de novo 510(k) clearance
Commercially available in the U.S.
2015
Commercially available in Canada
Launched ADVANCE Registry to evaluate data from 5,000 patients
2016
Commercially available in Japan
> 150 peer-reviewed publications
> 150 issued and allowed patents worldwide2017
NICE Guidance recommends HeartFlow
> 10,000 patients worldwide have received the HeartFlow Analysis
Announced collaboration with Siemens Healthineers
2018
Innovation and Technology Payment Program Awarded by NHS England
Received reimbursement approval in Japan from MHLW
Launched PRECISE Randomized Clinical Trial
2019
Named one of the World’s Most Innovative Companies by Fast Company
FDA Clearance Received for HeartFlow Planner
2020
FORECAST trial results show increased treatment efficiency with HeartFlow Analysis
JAMA Network Open Publication Demonstrates the Coronary CT-HeartFlow Analysis Pathway is ‘Dominant’ Compared to Stress Testing in Cost-Effectiveness Analysis
2021
NHS England and NHS Improvement mandate adoption of AI-powered HeartFlow Analysis to fight coronary heart disease
Completes Patient Enrollment in the PRECISE Trial
125675228 v1